AstraZeneca PLC (AZN)vsCryoCell International Inc (CCEL)
AZN
AstraZeneca PLC
$168.37
-2.99%
HEALTHCARE · Cap: $257.57B
CCEL
CryoCell International Inc
$3.99
-4.09%
HEALTHCARE · Cap: $35.48M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 197042% more annual revenue ($61.37B vs $31.13M). AZN leads profitability with a 17.0% profit margin vs -7.9%. AZN appears more attractively valued with a PEG of 1.19. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
CCEL
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$168.37
$27.44 discount
Margin of Safety
+33.9%
Fair Value
$5.05
Current Price
$3.99
$1.06 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Every $100 of equity generates 129 in profit
Earnings expanding 72.1% YoY
Conservative balance sheet, low leverage
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Revenue declined 1.9%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : CCEL
The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : CCEL
The primary concerns for CCEL are Market Cap, Revenue Growth, Altman Z-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while CCEL is a turnaround play — different risk/reward profiles.
CCEL carries more volatility with a beta of 0.55 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 50/100), backed by strong 17.0% margins. CCEL offers better value entry with a 33.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
CryoCell International Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?